Loading...
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
Moeller, Nora Praditya, Dimas Kinast, Volker Friesland, Martina Engelmann, Michael Verhoye, Lieven Sayed, Ibrahim M Behrendt, Patrick Dao Thi, Viet Loan
Moeller, Nora
Praditya, Dimas
Kinast, Volker
Friesland, Martina
Engelmann, Michael
Verhoye, Lieven
Sayed, Ibrahim M
Behrendt, Patrick
Dao Thi, Viet Loan
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2018-09-01
Submitted date
Files
Loading...
Open Access article
Adobe PDF, 1.49 MB
Other Titles
Abstract
Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genus Orthohepevirus in the family Hepeviridae. HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin is the treatment of choice for most patients and type I interferon (IFN) has been evaluated in a few infected transplantation patients in vivo. However, no effective and specific treatments against HEV infections are currently available. In this study, we evaluated the natural compound silvestrol, isolated from the plant Aglaia foveolata, and known for its specific inhibition of the DEAD-box RNA helicase eIF4A in state-of-the-art HEV experimental model systems. Silvestrol blocked HEV replication of different subgenomic replicons in a dose-dependent manner at low nanomolar concentrations and acted additive to ribavirin (RBV). In addition, HEV p6-based full length replication and production of infectious particles was reduced in the presence of silvestrol. A pangenotypic effect of the compound was further demonstrated with primary isolates from four different human genotypes in HEV infection experiments of hepatocyte-like cells derived from human embryonic and induced pluripotent stem cells. In vivo, HEV RNA levels rapidly declined in the feces of treated mice while no effect was observed in the vehicle treated control animals. In conclusion, silvestrol could be identified as pangenotypic HEV replication inhibitor in vitro with additive effect to RBV and further demonstrated high potency in vivo. The compound therefore may be considered in future treatment strategies of chronic hepatitis E in immunocompromised patients.
Citation
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
Description
Series/Report no.
ISSN
1872-9096
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 3.0 United States